Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 4,129 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neck Neoplasms Clear all

Conditions: Candidiasis, Oral, Thrush, Candidiasis
Interventions: Frio Oral Rinse; Drug
Lead sponsor: Biomedical Development Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Kansas City, Missouri • San Antonio, Texas

Conditions: Head and Neck Cancer
Interventions: Pembrolizumab, Surgery, Radiation Therapy, Cisplatin; Drug · Procedure · Radiation
Lead sponsor: Trisha Wise-Draper; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 6
States / cities: Louisville, Kentucky • Ann Arbor, Michigan • Cincinnati, Ohio + 3 more

Conditions: Smoking
Interventions: Telephone Counseling, Telephone Assessments; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 370 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Thyroid Cancer
Interventions: Not listed
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections, Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Interventions: Group Meeting (Focus Group), Questionnaires; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Adenocarcinoma of Esophagus, Squamous Cell Carcinoma of Esophagus
Interventions: Cetuximab, Cisplatin, Irinotecan, Radiation therapy, Surgery; Drug · Device · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Head and Neck Cancer
Interventions: Cisplatin, Paclitaxel, Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation, Triple endoscopy and biopsy; Drug · Radiation · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Head and Neck Neoplasms
Interventions: Pembrolizumab 200 mg, Radiotherapy 60 Gray, Radiotherapy 66 Gray, Radiotherapy 70 Gray, Cisplatin 100 mg/m^2; Biological · Radiation · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 68
States / cities: La Jolla, California • Los Angeles, California • Newport Beach, California + 56 more

Conditions: Advanced Solid Tumors
Interventions: BGB-30813, Tislelizumab; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Hackensack, New Jersey • Houston, Texas • San Antonio, Texas

Conditions: Oral Cavity Neoplasm
Interventions: High-Resolution Microendoscopy, Multispectral Imaging, Proflavine; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cervical Cancer, Precancerous Condition
Interventions: Colposcopic biopsy, Light-Scattering Spectroscopy; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,070 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Gynecologic Cancer, Neck Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Thoracic Cancer, Cutaneous Tumor, Urologic Cancer, Neurologic Cancer, Lymphoma, Sarcoma, Bone Marrow Transplant
Interventions: Lay Navigation; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 1,053 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Oropharyngeal Neoplasms
Interventions: chemotherapy, radiotherapy, Reduced dose radiotherapy; Drug · Radiation
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Cervical Cancer
Interventions: Lay Health Advisor Education Intervention, Usual Care Group; Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: PD-1inhibitor - LVGN 3616, CD 40 Agonist - LVGN 7409; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Thyroid Nodules, Pulsed Field Ablation
Interventions: Questionnaire; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC), Urothelial Carcinoma, Malignant Melanoma
Interventions: Phase 1a: LB-LR1109, Phase 1b: LB-LR1109 and Atezolizumab; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: HNSCC,Larynx, Pharynx and Oral Cavity, Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Surgery
Interventions: Panitumumab-IRDye800, [18F]NOTA-ABY-030; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cervical Cancer, HEENT Cancer, Renal Cancer, Uterine Cancer, CERVIX UTERI NOS, RECTUM
Interventions: 124I-Iodo-Azomycin Galacto-Pyranoside; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Head and Neck Carcinoma
Interventions: Image-Guided Surgery, Indocyanine Green Drug; Procedure · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes, Cervical Cancer (Early Detection), Obesity & Overweight
Interventions: patient navigation and self-collection; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 25 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: DDD, Deformity, Tumor, Fracture
Interventions: Not listed
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 6
States / cities: Montgomery, Alabama • Tallahassee, Florida • Indianapolis, Indiana + 3 more

Conditions: Esophageal Cancer, Advanced Esophageal Cancer, Gastric Cancer, Advanced Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Cancer
Interventions: Intratumoral 2141-V11, Nivolumab, Fluoropyrimidine; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Biliary Tract Carcinoma
Interventions: IDE892, IDE397; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 23
States / cities: Goodyear, Arizona • Phoenix, Arizona • Duarte, California + 19 more

Search by objective public record fields.

Novel Rinse to Treat in Oral Candidiasis in Cancer Patients

Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma

Combined Treatment for Tobacco and Alcohol Use in Puerto Rico

Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.

People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity

Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer

Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery

Fluorescence and Reflectance Spectroscopy During Colposcopy in Detecting Cervical Intraepithelial Neoplasia and Dysplasia in Healthy Participants With a History of Normal Pap Smears

Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study

Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity

Community Awareness Resources and Education - Project 1

CD40 Agonist and PD-1 Inhibitor in HNSCC

Nanosecond Pulsed Field Ablation in the Management of Benign Thyroid Nodules

Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma

Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors

Near-Infrared Image Guided Surgical Resection With Indocyanine Green in Treating Patients With Head and Neck Cancer

Improving Cervical Cancer Prevention Among Women Living With Chronic Conditions.

MaxAn Post Market Surveillance Validation

A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors